Skip to content

Asset turnover at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
0.4×0.0×
Ardelyx logo
ArdelyxARDX
0.9×0.0×
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
+0.1×
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
0.9×-0.5×
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
0.7×+0.1×
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
0.6×-0.1×

Other financials

Income statement

See full
Revenue$106.5M+159%
Operating income$72.6M+349%
Net income$40.8M+209%
EPS (diluted)$0.24+204%

Balance sheet

See full
Cash & equivalents$220.5M+103%
Total debt$212.4M+1,323%
Total equity-$217.1M+35.0%
Total assets$434.6M+32.8%

Cash flow

See full
Operating cash flow$5.1M-74.3%
CapEx-
Free cash flow$74.6M+390%

Valuation

See full
Market cap$632.12M+457%
Enterprise value$624M+3,024%
P/E6.2×
P/S1.8×+1.4×

Profitability

See full
Gross margin99.2%
Operating margin55.4%+38.7pp
Net margin28.3%+22.3pp
FCF margin24.7%-11.1pp

Returns & leverage

See full
Return on equity29.7%-138pp
Debt / equity-0.5×
Current ratio1.4×-1.9×

Where this comes from

Calculated from Ironwood Pharmaceuticals’s reported figures.

Based on trailing twelve months.

The official record: Ironwood Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ironwood Pharmaceuticals's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ironwood Pharmaceuticals's asset turnover?
Ironwood Pharmaceuticals (IRWD) reported asset turnover of 0.9× in Q1 2026.
How has Ironwood Pharmaceuticals's asset turnover changed year-over-year?
Ironwood Pharmaceuticals's asset turnover increased by 14.4% year-over-year, from 0.8× to 0.9×.
What is the long-term trend for Ironwood Pharmaceuticals's asset turnover?
Over 5 years (2020 to 2025), Ironwood Pharmaceuticals's asset turnover has grown at a -0.4% compound annual growth rate (CAGR), from 0.8× to 0.8×.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.